Seed 5A Convertible Preferred Stock Opportunity
Round Target:
$5,000,000
Current Valuation:
$29.7M
Price Per Share:
$2.62
Investment Minimum:
$50k
Features:
PCAOB (Audited Financials)
Qualified Small Business Stock (IRC 1202)
Reg D 506(C) Offering
Trethera's Drug, TRE-515, is in clinical trials today.
378% Company Value Growth
Since 2021, Trethera’s internal valuation has surged through scientific breakthroughs and strategic investment.
Over $7 Million in NIH Grants
NIH grant funding matches investor contributions, significantly reducing financial risk. These non-dilutive grants are not loans and do not require repayment.
FDA Designated Orphan Drug Status
Trethera has received FDA Orphan Drug Designation for two autoimmune indications, unlocking 7 years of market exclusivity upon approval, approximately $4 million in waived FDA fees, and valuable tax incentives — all of which reduce development costs and strengthen the company’s competitive position.
Patent Protection
Trethera holds multiple issued and granted patents from the USPTO, including exclusive rights to its lead asset, TRE-515, which is protected by patent coverage through at least 2041.
Our Product
A Single Pill with Transformative Potential
TRE-515: A once-daily, well-tolerated treatment targeting multiple diseases with one breakthrough solution.
Many patients with cancer and autoimmune diseases face limited treatment options with severe side effects. TRE-515 is designed to potentially offer a safer, more effective, more convenient solution, targeting cancers and autoimmune diseases at their root.
Mice with Multiple Sclerosis (MS) show remarkable improvement when treated with TRE-515.
From Hospice to Hope
A Life-Changing Journey with TRE-515
- Patient faced an impossible choice: enter hospice care or try an experimental drug, hoping to survive 40 more days.
- With Trethera’s groundbreaking therapy, she defied the odds, thriving for 252 days instead of just 40.
- Not only did she survive, but she celebrated Christmas with her family and took a European vacation with her daughters.
- TRE-515 gave her the chance to live life again—far beyond what anyone had imagined. This is the power of innovation in action.
Patient’s true identity protected.
Bringing TRE-515 to Patients and Creating Value for Investors
Get to know the experienced leaders behind Trethera, whose expertise and dedication are guiding us toward a future of life-changing breakthroughs.
Kenneth Schultz, MD
Chairman, CEO, & President
Previous leadership roles at Halozyme, Medtronic, and McKinsey & Company.
Cary Talbot
Chief Operating Officer
Previous leadership roles at Medtronic and Hughes Missile Systems.
Evelina Rubinchik, PHD
Preclinical Development
Previous leadership roles at Migenix and Micrologix.
Joyce James, PHD
Clinical Pharmacology
Previous leadership roles at Lyric, Cytokinetics, and Merck.
Chris Santos
Manufacturing
Previous leadership roles at Illumina, Kalypsys, and Victory.
